Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism
Zanin-Zhorov A, Weiss J, Nyuydzefe M, Chen W, Scher J, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky M, Tonra J, Hippen K, Dustin M, Blazar B, Liu C, Waksal S. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 16814-16819. PMID: 25385601, PMCID: PMC4250132, DOI: 10.1073/pnas.1414189111.Peer-Reviewed Original ResearchConceptsT cellsIL-17IL-21Forkhead box P3 (Foxp3) expressionRegulatory T cell subsetsPhase 1 clinical trialCollagen-induced arthritisIL-17 secretionRegulatory T cellsRheumatoid arthritis patientsTreatment of autoimmunityBox P3 expressionT cell subsetsDevelopment of autoimmunityROCK2 inhibitorIFN regulatory factor 4Healthy human subjectsT cell receptor stimulationIL-21 promoterSTAT3-dependent mechanismRegulatory factor 4Human T cellsArthritis patientsSiRNA-mediated inhibitionProinflammatory cytokines